The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows

For those diagnosed with early-stage HR , HER2- #BreastCancer, the Oncotype DX Breast Recurrence Score® test means more than predicting whether they are likely to benefit from #chemotherapy.* It can mark an emotional turning point in the #CancerJourney. Learn more: http://spr.ly/61894MmRU recurrence-score-patients *Albain et al. Lancet Oncol. 2010;11(1):55-65; Paik et al. J Clin Oncol. 2006;24(24):3726-3734 | Until Everyone Knows

PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows